Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
7.78
Oct 21 • 3:59 PM ET Dollar change-0.07 Percentage change(-0.89%)
Aftermarket Close
7.77
Aftermarket • 7:30 PM ET Dollar change-0.01 Percentage change(-0.13%)
Index
-
Market Cap
448.83M
Enterprise Value
390.50M
Income
22.25M
Sales
191.85M
Book/sh
4.67
Cash/sh
1.22
Employees
462
IPO
May 31, 2013
P/E
20.38
Forward P/E
13.49
PEG
0.64
P/S
2.34
P/B
1.67
P/C
6.40
P/FCF
16.25
EV/EBITDA
9.06
EV/Sales
2.04
Quick Ratio
2.29
Current Ratio
4.06
Debt/Eq
0.04
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
0.38
EPS next Y
0.58
EPS next Q
0.13
EPS this Y
30.95%
EPS next Y
20.77%
EPS next 5Y
21.04%
EPS past 3/5Y
- -2.03%
Sales past 3/5Y
11.74% 6.25%
EPS Y/Y TTM
16.67%
Sales Y/Y TTM
13.17%
EPS Q/Q
25.10%
Sales Q/Q
22.72%
Insider Own
45.13%
Insider Trans
-0.76%
Inst Own
16.43%
Inst Trans
-3.32%
ROA
5.92%
ROE
8.40%
ROIC
7.97%
Gross Margin
40.82%
Oper. Margin
14.50%
Profit Margin
11.60%
SMA20
-3.74%
SMA50
-4.63%
SMA200
-3.02%
Trades
Shs Outstand
57.69M
Shs Float
31.66M
52W High
9.35 -16.79%
52W Low
6.55 18.78%
Volatility
2.22% 2.50%
ATR (14)
0.25
RSI (14)
44.40
Beta
0.91
Rel Volume
0.42
Avg Volume
121.29K
Volume
51,365
Perf Week
2.37%
Perf Month
-12.29%
Perf Quarter
11.78%
Perf Half Y
-6.94%
Perf YTD
10.20%
Perf Year
12.27%
Perf 3Y
78.44%
Perf 5Y
39.93%
Perf 10Y
39.68%
Prev Close
7.85
Price
7.78
Change %
-0.89%
Date Action Analyst Rating Change Price Target Change
Mar-21-25Initiated The Benchmark Company Buy $15
Jul-03-24Initiated Stifel Buy $18
Feb-02-18Initiated Chardan Capital Markets Buy $7
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brenner YaelVP QualitySep 14 '26Option Exercise5.9326,964159,89712,766Sep 17 11:40 AM
Livneh NirVP, General CounselSep 14 '26Option Exercise5.3710,00053,70010,000Sep 17 11:37 AM
Tsur DavidDirectorSep 14 '26Sale8.1822,827186,725407,929Sep 17 11:33 AM
Tsur DavidDirectorSep 08 '26Sale8.26162,7601,344,398430,931Sep 11 11:29 AM
Tsur DavidDirectorSep 07 '26Sale8.2814,238117,891593,691Sep 11 11:29 AM
Tsur DavidDirectorSep 09 '26Sale8.261751,446430,756Sep 11 11:29 AM
Tsur DavidDirectorSep 02 '26Option Exercise6.7149,000328,690634,429Sep 08 07:00 AM
Brenner YaelVP QualitySep 02 '26Option Exercise5.943,03618,0349,302Sep 08 07:00 AM
Brenner YaelVP QualityAug 26 '26Option Exercise6.2530,000187,50016,266Aug 31 07:00 AM
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment refers to specialty plasma therapies and normal source plasma (NSP). The Distribution segment focuses on the commercialization of in-licensed third-party biopharmaceutical products. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
Chief Executive OfficerMr. Amir London
Chief Financial OfficerMr. Chaime Orlev
Chief Operating OfficerMr. Eran Nir
Vice President of US Commercial OperationsMr. Jon R. Knight
Vice President of Business Development & Strategic ProgramsMr. Boris Gorelik